Short answer
Liquidia Corp (LQDA) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Liquidia disclosed litigation by United Therapeutics under the Hatch-Waxman Act.
Liquidia Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Liquidia disclosed litigation by United Therapeutics under the Hatch-Waxman Act
- Dispute concerns U.S. Patent No. 11,826,327 and Liquidia’s lead product, YUTREPIA inhalation powder
- Patent litigation creates potential regulatory and commercialization risk for YUTREPIA
- Exhibit 99.1 contains Liquidia’s press release and additional case details
Item EX-99.1 · Exhibit EX-99.1
- Claims 1 and 14 of U.S. Patent 11,826,327 found valid and infringed by YUTREPIA
- Remaining four asserted claims found invalid, narrowing United Therapeutics’ litigation win
- Court remedy decision pending, with proposals due within one week
- Potential outcomes range from removing PH-ILD labeling to broader YUTREPIA market restrictions
- Liquidia plans FDA label supplement and intends to pursue appeals; financial exposure remains unquantified
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Liquidia Corp 8-K filings
Get the next LQDA 8-K as it lands
Follow LQDA for push alerts, or ask the research agent what this filing means.